To include your compound in the COVID-19 Resource Center, submit it here.

Lessons learned from Carticel

Genzyme Biosurgery's Carticel autologous cultured chondrocytes for the repair of knee cartilage posted only $18.5 million in 2001 sales. But the company believes that a cardiovascular cell therapy, when combined with what it learned from developing Carticel, has far more potential. Thus GZBX last week partnered with Myosix S.A. to develop an autologous cardiac cell transplantation therapy to heal damaged heart muscles following infarction.


Read the full 656 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers